Recent Posts
Connect with:
Sunday / May 29.
HomeminewsLucentis First for Myopic CNV

Lucentis First for Myopic CNV

Lucentis has become the first intravitreal therapy licensed in Australia by the Therapeutic Goods Administration for the treatment of adults with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV).

CNV is an important cause of vision loss worldwide that often affects working-age adults. If left untreated, long-term visual outcomes of myopic CNV are generally poor.A pivotal trial investigating Lucentis in the treatment of myopic CNV demonstrated that Lucentis provides improvement in visual acuity compared with verteporfin photodynamic therapy (vPDT), the current licensed standard of care, as measured by the improvement in mean average BCVA change from baseline to month three.1

The mean change of BCVA from baseline at three months was +2.2 letters in the vPDT group of patients (n=55), and +10.6 letters in the Lucentis group of patients who received the recommended treatment regimen, which was based on disease activity (n=116) (p<0.00001). Improvement in BCVA from baseline was sustained at 12 months compared to baseline (+12.5 letters), with a mean number of 3.5 Lucentis injections over 12 months (median: 2 injections).2

Already available as a therapy for wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular oedema (DME) and visual impairment due to macular oedema that is secondary to retinal vein occlusion (RVO), Lucentis is now the first intravitreal therapy licensed in Australia in myopic CNV.

1. Neelam K et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495-525.
2. Approved Product Information for Lucentis. 28 April 2014.


By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.